Answers are grounded in this paper and cite their sources.
preclinical studies, propelling the clinical development of CAR NK-92 cells. Preliminary phase 1 data indicate that CAR NK-92 can be safely administered in the clinic. In this review, we provide an overview of recent advances in the research and clinical application of this novel cell immunotherapy.
No takes yet. Share an insight, caveat, or question.
Fabian et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: